Lifeboat Foundation

A research team led by the University of California, Irvine has engineered an efficient new enzyme that can produce a synthetic genetic material called threose nucleic acid. The ability to synthesize artificial chains of TNA, which is inherently more stable than DNA, advances the discovery of potentially more powerful, precise therapeutic options to treat cancer and autoimmune, metabolic and infectious diseases.

Bioengineered breast reconstruction and augmentation — dr. luba perry, phd — CEO, reconstruct bio.

Dr. Luba Perry, Ph.D. is Co-Founder and CEO of ReConstruct Bio (https://wyss.harvard.edu/technology/r…), an innovative venture emerging from Harvard’s Wyss Institute (https://wyss.harvard.edu/team/advance…), aimed at redefining the fields of medical reconstruction and aesthetics with an initial application of their groundbreaking technology on breast reconstruction and augmentation. With a multidisciplinary team of experts, the ReConstruct Bio team has developed the BioImplant—a living, bioengineered tissue created from the patient’s own cells, to provide safer, more natural alternative to current standards, which are often associated with significant drawbacks and health concerns.

Continue reading “Dr. Luba Perry, Ph.D. — CEO, ReConstruct Bio — Bioengineered Breast Reconstruction And Augmentation” »

Spider silk is one of the strongest materials on Earth, technically stronger than steel for a material of its size. However, it’s tough to obtain—spiders are too territorial (and cannibalistic) to breed them like silkworms, leading scientists to turn to artificial options.

Teaching microbes to produce the spider silk proteins through genetic engineering is one such option, but this has proved challenging because the proteins tend to stick together, reducing the silk’s yield. So, Bingbing Gao and colleagues wanted to modify the natural protein sequence to design an easily spinnable, yet still stable, spider silk using microbes.

The team first used these microbes to produce the silk proteins, adding extra peptides as well. The new peptides, following a pattern found in the protein sequence of amyloid polypeptides, helped the artificial silk proteins form an orderly structure when folded and prevented them from sticking together in solution, increasing their yield.

Researchers have discovered an antibody able to neutralize all known variants of SARS-CoV-2, the virus that causes COVID-19, as well as distantly related SARS-like coronaviruses that infect other animals.

As part of a new study on hybrid immunity to the virus, the large, multi-institution research team led by The University of Texas at Austin discovered and isolated a broadly neutralizing plasma antibody, called SC27, from a single patient. Using technology developed over several years of research into antibody response, the team led by UT engineers and scientists obtained the exact molecular sequence of the antibody, opening the possibility of manufacturing it on a larger scale for future treatments.

“The discovery of SC27, and other antibodies like it in the future, will help us better protect the population against current and future COVID variants,” said Jason Lavinder, a research assistant professor in the Cockrell School of Engineering’s McKetta Department of Chemical Engineering and one of the leaders of the new research, which was recently published in Cell Reports Medicine.

In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the development of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) systems. In 2020, the Nobel Prize in Chemistry was awarded to the scientists for the discovery of CRISPR–Cas9 system, a revolutionary genome editing technology that advanced DNA therapeutics. Subsequently, the CRISPR–Cas13 system has emerged as a potential tool to identify and rectify errors in RNA sequences. CRISPR–Cas13 is a novel technology is specifically engineered for virus detection and RNA-targeted therapeutics. The CRISPR RNA (CrRNA) targets specific and non-specific RNA sequences, and Cas13 is an effector protein that undergoes conformational changes and cleaves the target RNA. This RNA-targeting system holds tremendous promise for therapeutics and presents a revolutionary tool in the landscape of molecular biology.

Now, in a recently published BioDesign Research study, a team of researchers led by Professor Yuan Yao from ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, China has elucidated the latest research trends of CRISPR–Cas13 in RNA-targeted therapies. Talking about this paper, which was published online on 6 September 2024, in Volume 6 of the journal, Prof. Yao says, “By focusing on RNA-;the intermediary between DNA and proteins-;CRISPR-Cas13 allows scientists to temporarily manipulate gene expression without inducing permanent changes to the genome. This flexibility makes it a safer option in scenarios where genome stability is critical.”

RNA plays a central role in carrying genetic information from DNA to protein-synthesizing machinery, and also regulates gene expression and participates in numerous cellular processes. Defects in RNA splicing or mutations can lead to a wide variety of diseases, ranging from metabolic disorders to cancer. A point mutation occurs when a single nucleotide is erroneously inserted, deleted, or changed. CRISPR–Cas13 plays a role in identifying and correcting these mutations by employing REPAIR (RNA editing for programmable A-to-I replacement) and RESCUE (RNA editing for specific C-to-U exchange) mechanisms. Explaining the applications of Cas13-based gene editors, Prof. Yao adds, “The mxABE editor, for example, can be used to correct a nonsense mutation linked with Duchenne muscular dystrophy that can be corrected with mxABE. This approach has proved high editing efficiency, restoring dystrophin expression to levels more than 50% of those of the wild type.”

Hi folks, I’d like to invite you to a webinar I will be giving on my research, hosted by the Foresight Institute! It takes place this Friday at 12:00pm CST. You can sign up on the linked page. The donation is optional, so if you don’t want to donate, you can just put $0.00. I hope to see you there!

Biotech and Health Extension sponsored by 100 Plus Capital

Viruses inside vaults: a powerful new gene therapy delivery system

Continue reading “Logan Collins” »

Scientists have developed microscopic robots capable of treating brain aneurysms with unprecedented precision, offering a potential alternative to invasive brain surgeries. An international team, including researchers from the University of Edinburgh, engineered these nanorobots to safely and accurately deliver life-saving medications to the brain. This advancement comes in the context of a global health challenge, […].

The SARS-CoV-2 pandemic has had an unprecedented impact on global public health and the economy. Although vaccines and antivirals have provided effective protection and treatment, the development of new small molecule-based antiviral candidates is imperative to improve clinical outcomes against SARS-CoV-2. In this study, we identified UNI418, a dual PIKfyve and PIP5K1C inhibitor, as a new chemical agent that inhibits SARS-CoV-2 entry into host cells. UNI418 inhibited the proteolytic activation of cathepsins, which is regulated by PIKfyve, resulting in the inhibition of cathepsin L-dependent proteolytic cleavage of the SARS-CoV-2 spike protein into its mature form, a critical step for viral endosomal escape. We also demonstrated that UNI418 prevented ACE2-mediated endocytosis of the virus via PIP5K1C inhibition. Our results identified PIKfyve and PIP5K1C as potential antiviral targets and UNI418 as a putative therapeutic compound against SARS-CoV-2.

Despite the ongoing threat posed by new viruses following the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which led to the coronavirus disease 2019 (COVID-19) pandemic, new antiviral drugs continue to be developed to effectively block viral entry into the human body.

Professor Kyungjae Myung and his research team in the Department of Biomedical Engineering, affiliated with the IBS Center for Genomic Integrity, has discovered UNI418, a compound that effectively prevents the penetration of the coronavirus. This compound works by regulating dielectric homeostasis, thereby inhibiting the virus’s entry into human cells.

New research led by the Institute for Bioengineering of Catalonia (IBEC) has studied the migratory movement of groups of cells using light control. The results show that there is no leader cell that directs the collective movement, as previously thought, but that all cells participate in the process.